Indane Acetic Acid Compounds Modulate Immune Response to Reduce ARIA

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Alzheimer's disease, such as amyloid-beta directed antibodies, often lead to amyloid-related imaging abnormalities (ARIA) like vasogenic edema and hemosiderin deposits, which can cause severe side effects without effectively addressing the disease progression.

Innovation Solution

The use of indane acetic acids and their derivatives, which act as dual PPAR delta and gamma agonists, in combination with amyloid-beta directed antibodies, to treat Alzheimer's disease and reduce ARIA, by modulating immune responses and improving brain metabolism.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If amyloid-beta directed antibodies are used to treat Alzheimer's disease, then amyloid plaques are reduced, but amyloid-related imaging abnormalities (ARIA) and severe side effects occur

Engineering Contradiction:

Improveeffectiveness of Alzheimer's treatmentVSAvoidamyloid-related imaging abnormalities (ARIA)

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces indane acetic acid compounds as intermediary substances that modulate the immune response and reduce inflammation caused by amyloid-beta directed antibodies. These compounds act as mediators between the antibody therapy and the brain tissue, preventing the development of ARIA while maintaining the therapeutic effects of plaque reduction.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies preliminary anti-action by administering indane acetic acid compounds before or during amyloid-beta directed antibody treatment to prevent the formation of ARIA. This proactive approach counteracts the harmful effects before they manifest, allowing for safer and more effective Alzheimer's disease treatment.

Inventive Principle:

Principle #9Preliminary anti-action

2Productivity

If amyloid-beta directed antibodies are administered at higher doses to improve treatment efficacy, then amyloid plaque reduction increases, but the frequency and severity of ARIA increases

Engineering Contradiction:

Improveamyloid plaque clearance rateVSAvoidfrequency and severity of ARIA

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the parameter of immune modulation by introducing indane acetic acid compounds that alter the immune response to amyloid-beta directed antibodies. This parameter change allows for higher antibody doses to be administered effectively while maintaining safety, as the indane acetic acid compounds prevent the dose-dependent development of ARIA.

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If the blood-brain barrier is made more permeable to allow better drug penetration, then therapeutic efficacy improves, but the risk of harmful substances entering the brain increases

Engineering Contradiction:

Improvebrain penetration of therapeutic compoundsVSAvoidrisk of harmful substances in brain

Core Design Contradiction:

Ease of operationVSObject-affected harmful factors

Solution Approach 1:

The indane acetic acid compounds serve as protective intermediaries that selectively modulate the blood-brain barrier permeability. They allow therapeutic compounds to penetrate the brain effectively while maintaining the barrier's selective function, preventing harmful substances from entering the brain tissue.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250099434A1Methods of treating amyloid related brain disorders using novel compounds and antibodies

Publication Date: 2025.03.27 T3D THERAPEUTICS INC

AI summary

Novel indane acetic acid compounds alone or in combination with anti-amyloid beta antibodies, for the treatment of Alzheimer's disease, for the reduction of Amyloid-related imaging abnormalities (ARIA), and for the treatment of Cerebral Amyloid Angiopathy and vasogenic edema (VE).